2021 Speakers

VWS speaker

Rajinder Kumar Suri DCVMN

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dominique Maugeais Gavi, the Vaccine Alliance

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Martin Friede World Health Organization (WHO)

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Raches Ella Bharat Biotech

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Etleva Kadilli UNICEF

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Matthew Downham CEPI

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dr. Anh Wartel International Vaccine Institute

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Neelima Dwivedi MSD

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Ofer Levy Boston Children's Hospital, Harvard Medical School

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Scots Roberts Altimmune

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Ramesh Mathur Senior Biological E

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Jayesh Ranjan Government of Telangana

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Arun Kumar CEPI

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Remko Van Leeuwen INDIGO

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dr. Farshad Guirakhoo COVAXX and VAXXINITY

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dr. Sanjay Singh Gennova Pharmaceuticals

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Ashish Sahai Serum Institute of India

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Li Shi Shanghai Zerun Biotechnology

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dr. Vickneshwaran Muthu Disease Control Division Ministry of Health, Malaysia

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Kapil Maithil Zydus Cadila

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dr. Ming Ni Plasmid Virus R&D Department

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

VWS speaker

Dr. Harshad Patil Interactive Research School for Health Affairs

Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025.

The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.

Moreover, this congress will have a special focus on the COVID-19 vaccine development. COVID-19 has affected over 105 million people with more than 2 million deaths across the world since its origination in Wuhan, China in December 2019. Since then, there have been several companies and organizations that are racing towards developing a viable vaccine. Developing a vaccine, in a usual circumstance, takes about 10 years. However, all vaccine stakeholders have accelerated coronavirus vaccine development across all stages – from testing to regulatory reviews and expect a viable vaccine to be available within the next 12-18 months.

Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration. For more details on the program, download the brochure here.

Don't Miss Out on Vaccines World Summit 2021

Speaking Opportunities

Pavithra Selvam
Conference Producer

Registration & Media

Rima Karan
Marketing Executive

Sponsorship & Exhibition

Ana Laxamana
Business Development Manager
en_USEnglish
Open chat
Come chat with us!
Hello! How can I help you?

Kindly fill in your details below to receive a copy of the Preliminary Program.
Thank you for your interest and cooperation!

    Products of Interest*
    Blood & Plasma ProductsAntibody TherapeuticsCell TherapyGene TherapyProtein TherapeuticsViral VaccinesImmunotherapeuticsOther BiologicsNon-biologicsMedical DeviceNone of the above

    Subscribe to our mailing list

    Kindly fill in the form below to receive the Sponsorship Prospectus by email.
    Thank you for your interest and cooperation!

      Products of Interest*
      Blood & Plasma ProductsAntibody TherapeuticsCell TherapyGene TherapyProtein TherapeuticsViral VaccinesImmunotherapeuticsOther BiologicsNon-biologicsMedical DeviceNone of the above

      Subscribe to our mailing list

      Non-Singapore Companies, kindly visit the registration page here.
      Singapore Companies, kindly visit the registration page here.